

Synthesis of Polynuclear Heterocyclic Compounds Derived from 1-Biphenyl-4-yl-4-(1-methyl-1H-benzimidazol-2-yl)-but-2-en-1-one with Expected Biological Activity

N. A. Mahmoud¹, Inas Ezz Eldin Islam¹ and Enas A. Hasan²

¹Chemistry Department, Faculty of Science (Girls), Al-Azhar University, Nasr City, and

²Egyptian Organization for Biological Products & Vaccines (Vacsera), Cairo Egypt

NUCLEOPHILIC addition of barbituric acid, thioglycolic acid with malononitrile and 3-Amino-5-pyrazolinone with 1-Biphenyl-4-yl-4-(1-methyl-1H-benzimidazol-2-yl)-but-2-en-1-one (1) gives pyrimidine, Thiazol and pyrazolinone derivatives (2-4), respectively.

Compound 4 which reacted with Arylidene malononitrile in ethanol to give pyrano derivatives (5).

Cyclocondensation of chalcone (1) with thiourea under reflux in ethanolic NaOH led to thiazine derivative (6) and treatment of (6) with bromine – acetic acid mixture afforded compound (7) similarly, cyclization of chalcone (1) with orthophenylenediamine in Dimethylformamide (DMF) gave diazepine derivatives (8).

Also, chalcone (1) reacted with 3-Amino-5-pyrazolinone in ethanol to give pyrazolinone derivative (9). (Scheme 1).

The condensation of compound (1) with 2-cyanoacetohydrazide through the acid-catalyzed reaction to form the Schiff base (10) by heating in 96% acetic acid gave the diazetidine derivative (11) which upon reaction with phosphorous oxychloride gave the chlorodiazetidine derivative (12), the latter compound reacted with 2ry amines and yielded the substituted amino diazetidine derivatives (13_{a-c}).

On the other hand, the Schiff bases (14) produced from condensed compound (1) with 2-Amino-2-(hydroxy methyl) propane-1,3-diol in ethyl alcohol which reacted with phosphorous oxychloride gave the propanol derivatives (15).

Finally, the cyclization reaction of compound (1) with 2-aminophenol and 2-aminothiophenol in dry benzene formed compounds (16, 17), respectively. (Scheme 2).

Introduction

Benzimidazole derivatives are of wide interest because of their diverse biological activity and clinical application [1]. This ring system is present in numerous anti-parasitic, fungicidal, anti-inflammatory drugs [2], anti-hypertensive, anti-viral, anti-tumour, anti-helminthic, anti-microbial, anti-oxidant, anti-ulcer, anti-amoebic, anti-histaminic activity, anti-bacterial, antipsychotic, antiprotozoal, antineoplastic, analgesic, anti dopaminergic, anti-hepatitis B virus, anticonvulsant, CNS depressant, anti-parkinson.

In addition, benzimidazoles are very important precursors in organic synthesis as (vitamin B12). Constituents are a milestone in the chemistry of benzimidazoles and antidiabetic activity (3-24).

Synthesis of benzimidazolyl chalcones which have been used as intermediate for the synthesis of bioactive heterocyclic compounds vis, pyrimidine-2,4,6-trione [25], thiazol-4-one [26], pyrazol-3-one [27], 1,7a-dihydro-pyrano [2,3-c] pyrazole-5-carbonitrile [28], thiazin-2-yl-amine [29], 1H-benzo[b][1,4]diazepine, benzocycloheptene and benzo[b][1,4]thiazepin

[30], allylidene-hydrazide, 1,2 diazetidene-3-carbonitrile, 1H-isoindol-2-yl, 4-morpholin-4-yl, 4-piperidin-1-yl, allylidene amino-propan-1-ol-1,2-diol, which have high biological activity as antimicrobial and anticancer activity.

Results and Discussion

The new derivatives were prepared according to the reaction sequences depicted in Schemes 1 & 2.

Nucleophilic addition of barbituric acid, thioglycolic acid with malononitrile and 3-Amino-5-pyrazolinone [31] with 1-Biphenyl-4-yl-4-(1-methyl-1H-benzimidazol-2-yl)-but-2-en-1-one (1) gave 5-[5-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-5-oxo-pentyl]-pyrimidine-2,4,6-trione (2), 5-[3-Biphenyl-4-yl-1-(1-methyl-1H-benzimidazol-2-yl)-3-oxo-propyl]-2-methyl-thiazol-4-one(3), 5-[1-Biphenyl-4-yl-1-(1-methyl-1H-benzimidazol-2-yl)-allylidenamino]-2,4-dihydro-pyrazol-3-one (4) which reacted with Arylidene malononitrile in ethanol to give 6-Amino-3-[1-biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylideneamino]-4-(4-methoxy-phenyl)-1,7a-dihydro-pyrano[2,3-c]pyrazole-5-carbonitrile (5).

Cyclocondensation of chalcone (1) with thiourea under reflux in dry ethanol in the presence of few drops of glacial acetic acid gave the corresponding 6-Biphenyl-4-yl-4-(1-methyl-1H-benzimidazol-2-yl)-5,6-dihydro-4H-[1,3]thiazin-2-yl-amine (6) and by treatment with bromine, acetic acid mixture afforded compound 6-Biphenyl-4-yl-5-Bromo-4-(1-methyl-1H-benzimidazol-2-yl)-6H-[1,3]thiazin-2-yl-amine (7).

Similarly, cyclization of chalcone (1) with orthophenylenediamine in glacial acetic acid gives 4-Biphenyl-4-yl-2-(1-methyl-1H-benzimidazol-2-yl)-1H-benzo[b][1,4]diazepine (8), by reaction of 3-Amino-5-pyrazolinone with chalcone (1) in ethanol containing T.E.A to form 5-Amino-4-[3-biphenyl-4-yl-1-(1-methyl-1H-benzimidazol-2-yl)methyl]-3-oxo-propyl]-2,4-dihydro-pyrazol-3-one (9). (Scheme 1).

Also, chalcone (1) reacted with 2-cyanoacetohydrazide in acetic acid to form Schiff base cyano-acetic acid [1-biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidene]-hydrazide (10) and by heating in 96% acetic

acid gave 2-[Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-oxo-[1,2]diazetidene-3-carbonitrile (11), which upon reaction with phosphorous oxychloride gave 2-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-chloro-[1,2]diazetidene-3-carbonitrile (12).

The latter compound reacted with 2^{ry} amines and yielded the substituted amino diazetidene derivative(13a-c) 2-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-(1H-isoindol-2-yl)-[1,2]diazetidene-3-carbonitrile (13a), 2-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-morpholin-4-yl-[1,2]diazetidene-3-carbonitrile (13b) and 2-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-piperidin-1-yl-[1,2]diazetidene-3-carbonitrile(13c), respectively.

On the other hand, the Schiff bases of 3-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidene amino]propan-1-ol-1,2-diol (14) resulted from condensed compound (1) with 2-amino-2-(hydroxy methyl)propane-1,3-diol in ethyl alcohol which reacted with phosphorous oxychloride to give [1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidene]-propyl-amine (15).


Finally, the cyclization of chalcone (1) with 2-aminophenol and 2-aminothiophenol in dry benzene formed 8-Biphenyl-4-yl-6-(1-methyl-1H-benzimidazol-2-yl)-5-oxo-9-azabenzocycloheptene and 4-Biphenyl-4-yl-2-(1-methyl-1H-benzimidazol-2-yl)-benzo[b][1,4]thiazepine (16,17), respectively (Scheme 2).

Experimental


Melting points were determined in open capillary tubes on an electrothermal 9100 digital melting point apparatus (Buchi, stritzerland) Elmer 2400 analyzer (USA).

IR spectra were recorded on a Perkin-Elmer 160 FTIR (USA) as KBr. The ¹H-NMR and ¹³C-NMR spectra were measured on Bruker DRX 500 and 125 MHz at Max-Planck Institute, Germany in DMSO-d₆.

The elemental analysis were carried out at microanalytical, Faculty of Science, Cairo University by using Perkin-Elmer 2400 C, H, N elemental analyzer.



Scheme (1)



Scheme (2)

Synthesis of 1-(Biphenyl-4-yl)-4-(1-methyl-1H-benzimidazol-2-yl)-but-2-en-1-one (1)

To a solution of [4-(1H-benzimidazol-2-yl)-(1-biphenyl-4-yl)-but-2-en-1-one] in methanol (20 ml) is treated with methanolic sodium hydroxide solution (25 ml; 20%) and then chloroacetic acid (0.01 mol) is added dropwise with continuous shaking. The reaction mixture is refluxed for 2 hr and treated with dilute HCl and the solid obtained was recrystallized from benzene to give compound (1).

Synthesis of 5-[5-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-5-oxo-pentyl]-pyrimidine-2,4,6-trione (2)

To a solution of (1) (0.01 mol) in dry benzene (20 ml), Barbituric acid (0.01 mol) was added. The reaction mixture was refluxed for 10 hr, the solid separated on cooling was crystallized from ethanol to give (2). FT-IR (KBr, ν , cm^{-1}) 3406, 3170 (2NH), 1624, 1654, 1685 (2C=O, C=N), 1558 (C=C), 1303 (CH_3). $^1\text{H-NMR}$ spectrum DMSO d_6), 3.8 (S, 3H, CH_3), 7.7-7.1 (m, 15, 2 CH_2 , ArH), 10.2 (S, H, NH), 13.8 (S, H, NH), 1.5 (dd, 2H, CH_2).

Synthesis of 5-[3-(Biphenyl-4-yl)-1-(1-methyl-1H-benzimidazol-2-yl)-3-oxo-propyl]-4-oxo-4,5-dihydro-2-methyl-thiazol-2-yl-acetonitrile (3)

To a solution of (1) (0.01 mole) and malononitrile (0.01 mol) and thioglycolic acid (0.01 mol) in ethanol (50 ml) and catalytic amount of piperidine was heated under reflux for 5 hr. The reaction mixture was cooled at room temperature and the solution was concentrated by evaporation of the solvent and then the product was collected and recrystallized from ethanol. FT-IR (KBr, ν , cm^{-1}) 1600 (C=O), 1581 (C=C), 1400 (CH_3), 2110 (CN). The mass spectrum (EL/MS) shows molecular ion peak at $m/z = 478$ (23 %) and base peak at $m/z = 190$.

Synthesis of 5-[1-Biphenyl-4-yl-1-(1-methyl-1H-benzimidazol-2-yl)-allylidenamino]-2,4-dihydro-pyrazol-3-one (4)

To a solution of compound (1) (0.01 mol) in acetic acid (96%) was added 3-Amino-5-pyrazolinone (0.01 mol). The reaction mixture was stirred at room temperature for 7 and 10 hr. The solid product which formed was filtered off, washed with water, air dried and recrystallized from absolute ethanol to give the title compound. FT-IR (KBr, ν , cm^{-1}) 3402 (NH), 1600 (C=O), 1342 (CH_3). $^1\text{H-NMR}$ spectrum (DMSO- d_6), 3.3 (S, 3H, CH_3), 7.5-7.1 (m, 13H, Ar-H), 7.7-7.6

(dd, 2H, CH=CH), 2.4 (S, H, CH_2), $^{13}\text{C-NMR}$ 25.1 (CH_3), 192.4 (C=O), 18.1 (CH_2), 82.2 (CH=CH).

Synthesis of 6-Amino-3-[1-biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidenamino]-4-(4-methoxy-phenyl)-1,7a-dihydro-pyrano [2,3-c] pyrazole-5-carbonitrile (5)

To a solution of (4) (0.01 mol) and arylidene malononitrile (0.01 mol) in ethanol (50 ml) on heating under reflux for 7 hr, the reaction mixture was cooled and the product was collected by filtration and recrystallized from petroleum ether (40-60). FT-IR (KBr, ν , cm^{-1}) 3417, 3059 (NH₂, NH), 2191 (CN), 1307 (CH_3), 1512 (C=C), 1604 (C=N), 1253 (C-O), 1114 (OCH₃). The mass spectrum (EL/MS) shows molecular ion peak at $m/z = 603/604$ M/M⁺ (3.9%) and base peak at $m/z = 181$.

Synthesis of 6-Biphenyl-4-yl-4-(1-methyl-1H-benzimidazol-2-yl)-5,6-dihydro-4H-[1,3] thiazin-2-yl-amine (6)

To a solution of chalcone (1) (0.01 mol) and thiourea (0.01 mol) were dissolved in ethanolic NaOH (10 ml) stirred for 3hr by using a magnetic stirrer and then pored into 200 ml water with continuous stirring, this was kept in cold condition in refrigerator for 24 hr, the precipitate obtained was filtered, washed and recrystallized from ethanol to give (6). FT-IR (KBr, ν , cm^{-1}) 3421 (NH₂), 1608 (C=N), 1423 (CH_3), $^1\text{H-NMR}$ spectrum (DMSO- d_6), (δ , ppm), 3.3 (S, 3H, CH_3), 7.6-6.6 (m, 14H, CH-thiazine, Ar-H), 7.8 (S, 2H, NH₂), 1.3 (dd, 2H, CH_2 -thiazine), 10.7 (S, H, CH-thiazine).

Synthesis of 6-Biphenyl-4-yl-5-Bromo-4-(1-methyl-1H-benzimidazol-2-yl)-6H-[1,3]thiazin-2-yl-amine (7)

A solution of (21) (0.01 mol), in glacial acetic acid (20 ml) was stirred and treated portionwise with Bromine (0.01 mol) at 60-70 °C. The solution was further stirred for 2 hr, then cooled in ice. The precipitate product was filtered, washed with light petroleum ether (40-60), stirred with concentrated ammonium hydroxide for 15 min. The solid product was recrystallized from benzene to give (7). 3431 (NH₂), 1677 (C=N), 1365 (CH_3), 706 (Br).

Synthesis of 4-Biphenyl-4-yl-2-(1-methyl-1H-benzimidazol-2-yl)-1H-benzo[b][1,4] diazepine (8)

To a solution of chalcone (1) (0.01 mol) and orthophenylene diamine (0.01 mol) in Dimethylformamide (30 ml) containing added

amount of glacial acetic are refluxed on water bath for 9-10 hr, then cooling down to room temperature, and the precipitate obtained is filtered and recrystallized from petroleum ether (60-80). FT-IR (KBr, ν, cm^{-1}) 3029(NH), 1300(CH₃), 1599(C=C), 1659(C=N), its ¹H -NMR spectrum (DMSO-d₆) reveals signals (δ , ppm) 7.7-6.8 (m, 18H, Ar-H), 8.2 (s, H, NH), 3.3 (s, 3H, CH₃), ¹³C-NMR, 22.5 (CH₃), 142.3-115.7 (Ar-C), 139.5 (C=N).

Synthesis of 5-Amino-4-[3-biphenyl-4-yl-1-(1-methyl-1H-benzimidazol-2-yl)methyl]-3-oxo-propyl]-2,4-dihydro-pyrazol-3-one (9)

To a solution of 3-Amino-5-pyrazolinone (0.01 mol) in absolute alcohol (15 ml) containing triethylamine (0.5 ml) compound (2) is added (0.01 mol), the reaction mixture was stirred at room temperature for 7 and 10 hr.

The solid formed after adding water (20 ml) is filtered off, washed with water, air dried and recrystallized from absolute ethanol to give the title compound. FT-IR (KBr, ν, cm^{-1}) 1678, 1620 (2C=O), 3250, 3062 (NH₂, NH), 1381(CH₃), 1527 (C=C).

Synthesis of cyano-acetic acid [1-biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidene]-hydrazide (10)

To a solution of compound (1) (0.01 mol) in acetic acid (10 ml) is added 2-cyanoacetohydrazide (0.01 mol). The reaction mixture is stirred at room temperature for 30 min, the solid formed is filtered off, washed with water, air dried and recrystallized from absolute ethanol. FT-IR (KBr, ν, cm^{-1}) 3186(NH), 1685 (C=O), 1624(C=O), 1685, 1624 (2C=O), 1357(CH₃), its ¹H -NMR spectrum (DMSO-d₆), (δ , ppm) 7.9-6.8 (m, 13H, Ar-H), 13.9 (s, H, NH), 8.07 (dd, 2H, CH=CH), 3.3 (s, 2H, CH₂).

Synthesis of 2-[Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-oxo-[1,2] diazetidene-3-carbonitrile (11)

Compound (10) (0.01 mol) is heated under reflux in acetic acid (96 %) for 5hr, the reaction mixture was then concentrated to 1/2 of its volume and left to cool at refrigerator. The product formed was collected by filtration, washed with water, air dried and recrystallized from ethanol. FT-IR (KBr, ν, cm^{-1}) 3280 (NH), 2130(CN), 1662 (C=O), 1411(CH₃), 1597 (C=C).

Synthesis of 2-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-chloro-[1,2] diazetidene-3-carbonitrile (12)

A solution of compound (11) (0.01 mol) in phosphorus oxychloride (50 ml) was heated under reflux for 3hr, the reaction mixture was cooled and then poured into ice-water while stirring; the solid that formed was filtered off, washed with water, air dried and recrystallized from ethanol to give (12). FT-IR (KBr, ν, cm^{-1}) 1620 (C=N), 3414 (NH), 1384(CH₃), 744(Cl). ¹H -NMR spectrum (DMSO-d₆), reveals signals (δ , ppm) 7.6-6.8 (m, 14H, CH, Ar-H), 7.7 (dd, 2H, CH=CH), 3.5 (s, 3H, CH₃), 12.2 (s, H, NH), 13.7 (s, H, CH-diazetidene).

Synthesis of 2-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allyl]-4-(1H-isoindol-2-yl), 4-morpholin-4-yl and 4-piperidin-1-yl-[1,2] diazetidene-3-carbonitrile (13 a-c)

A solution of (12) and appropriate secondary amines (0.01 mol) in dry dioxane (15ml) containing few drops of triethylamine was refluxed until the material disappeared for 7-12 hr, the solvent was then evaporated till dryness and the resulting residue was triturated with water (50 ml) and set aside overnight at refrigerator. The solid that formed is filtered off, and recrystallized from the proper solvent to give the title compounds. FT-IR (KBr, ν, cm^{-1}) 3417(NH), 1635(C=N), 1523(C=C), 1384 (CH₃), 2121(CN), 1620(C=N), 1384 (CH₃), 1516 (C=C), 3414 (NH), 2121 (CN).

Synthesis of 3-[1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidene amino]-propan-1-ol-1,2-diol (14)

To a solution of (2) (0.01 mol) in acetic acid (96 %) (10 ml) is added to 2-amino-2-(hydroxy methyl) propane-1,3 diol (0.01 mol), and the solid formed is filtered off, washed with water, air dried and recrystallized from absolute ethanol. FT-IR (KBr, ν, cm^{-1}) 1604(C=N), 1338(CH₃), 3433-3302 (3 OH), its ¹H -NMR spectrum (DMSO-d₆), 3.4 (t, H, CH₂OH), 3.7 (dd, 2H, CH₂OH), 8.17.2 (m, 13H, ArH), 9.8 (d, 2H, CH=CH), 2.5 (s, 2H, CH₂), ¹³C-NMR, 56.1 (CH₂OH), 23.1(CH₃), 129.5-127.3 (Ar-C), 85.2 (CH=CH).

Synthesis of [1-Biphenyl-4-yl-3-(1-methyl-1H-benzimidazol-2-yl)-allylidene]-propyl-amine (15)

A solution of compound (14) (0.01 mol) in phosphorus oxychloride (50 ml) is heated under reflux for 3hr, the reaction mixture is cooled down and then poured onto ice-water while

stirring, the solid formed is filtered off, washed with water, air dried and recrystallized from ethanol to give (15). FT-IR (KBr, ν , cm^{-1}) 1620 (C=N), 1384 (CH₃), 759 (Cl). The mass spectrum (EL/MS) shows molecular ion peak at $m/z = 497$ (2.8%) and base peak at $m/z = 68$.

Synthesis of 8-Biphenyl-4-yl-6-(1-methyl-1H-benzimidazol-2-yl)-5-oxo-9-aza-benzocycloheptene and 4-Biphenyl-4-yl-2-(1-methyl-1H-Benzimidazol-2-yl)-benzo[b][1,4]thiazepine (16,17)

To a solution of compound (1) (0.01 mol) in dry benzene (30 ml) is added to 2-aminophenol and 2-aminothiophenol (0.01 mol) with drops of glacial acetic acid, the reaction mixture is refluxed on the water bath (8-10 hr), the solids separated on cooling at room temperature, are recrystallized from ethanol to give the title compounds. FT-IR (KBr, ν , cm^{-1}) 1431 (CH₃), 1696 (C=N), 1111 (C-O-C), 1684 (C=N), 1313 (CH₃), 1571 (C=C). Its ¹H-NMR spectrum (DMSO-d₆), (δ , ppm) 2.5 (s, 3H, CH₃), 7.8-7.2 (m, 17H, Ar-H), 8.2 (s, H, CH-thiazepine)

Biological Activity

Antimicrobial activity

The antimicrobial activity of the synthesized compounds is determined in vitro using the disc diffusion [31].

All the synthesized compounds are screened for their antibacterial and antifungal activity in vitro by disc diffusion method using nutrient agar medium against following microorganisms, *Staphylococcus aureus* [ATCC 29213] *Bacillus subtilis* (Gram positive bacteria), *Escherichia coli* [ATCC 27853], *Pseudomonas aeruginosa* [ATCC 25922] (Gram negative bacteria) and fungal species like *Candida albicans*, *Aspergillus flavin* organisms.

Ampicillin is used as a positive control for antibacterial screening and an Amphotericin B is used as a positive control for antifungal screening. DMSO (Dimethylsulfoxide) is diluent which does not affect the growth of microbes (negative control). The tested compounds were dissolved in (DMSO). Filter paper discs (Whatman, 5 mm diameter) were saturated with former solution for bacterial test. The saturated filter paper discs were placed on the surface of solidified Czapek's Dox agar dishes seeded by test bacterial and fungal strains. The inhibition zones were measured in mm at the end of an incubation period of 48 hr at 28°C. The screening results have been tabulated in Table 1 and represented in Fig. 1 & 2.

TABLE 1. Antimicrobial study of the newly synthesized compounds of Part (II)

Comp. No.	Antibacterial activity				Antifungal Activity	
	Gram positive	Gram negative		<i>A. flavin</i>	<i>C. albicans</i>	
	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>			<i>P. aeruginosa</i>
	Inhibition zone diameter (mm)					
1	10	6	11	8	10	12
2	13	6	9	7	-	--
3	9	12	--	--	9	11
4	11	7	--	8	8	10
5	12	9	10	10	11	9
6	10	8	-	--	12	10
7	12	11	10	14	-	-
8	16	11	16	12	9	11
9	14	15	11	-	9	11
10	10	12	12	--	-	15
11	-	--	-	-	11	14
12	16	9	-	-	13	16
13	15	12	--	--	14	9
14	-	-	11	10	-	16
15	11	14	19	14	13	16
16	13	10	11	13	12	-
Ampicillin (antibacterial drug)	20	18	22	17	-	-




Fig.1 . Antibacterial activity of newly synthesized compounds.




Fig.2 . Antifungal activity of newly synthesized compounds.

Antiproliferative activity

All the newly synthesized compounds were tested for antiproliferative activity in vitro against different types of cancer cell lines as (HEPG2) human liver carcinoma cell line, (MCF-7) human breast cancer cell line and (HCT-116) human colon cancer cell line at different concentrations (100, 50, 25, 12.5, 6, 25.0) $\mu\text{g/ml}$, and the Doxorubicin, one of the most effective anticancer agents, was used as a reference drug. These cell lines were grown in RPMI -1640 medium supplemented with 2mg/ml sodium bicarbonate, 4.5 mg/ml glucose, 100 $\mu\text{g/ml}$ streptomycin sulphate, 40 $\mu\text{g/ml}$ gentamycin, 100 U/ml penicillin, as well as 10% (vol/vol) foetal bovine serum (FBS). All cell lines incubated at 37 °C in humidified air containing 5% CO_2 . Cytotoxicity was determined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) is a water soluble tetrazolium salt, which is converted to an insoluble purple formazan by cleavage of the tetrazolium ring by succinate dehydrogenase

within the mitochondria. The formazan product is impermeable to the cell membranes and therefore it accumulates in healthy cells [32].

Briefly, the Plate cells (104 –106 cells) in 200 μl PBS in 96-well (flat bottom). Add 20 μl of MTT solution, mix well, incubate for 4hr in 37°C and incubate additional 1hr in 37 °C in the dark. Then read plate in ELISA Reader – measure OD in 570 nm (background wavelength is 570 nm). IC50% ($\mu\text{g/ml}$), *i.e.* (50% inhibition concentration) was calculated for the tested compounds by using (sigmaplot software). The results of the IC50% of the compounds was tabulated (Table 2) and represented in Fig. 3.

Results and Discussion

From Table 1, the results showed that all the compounds have moderate sensitivity towards Gram positive bacteria compared to positive control (Ampicillin) except the compounds (11,

14) and all compounds showed slight to moderate sensitivity toward the Gram negative bacteria

except (3,4,6, 9,11,12,13) which showed no antibacterial activity.

Antiproliferative activity of the newly synthesized compounds against human carcinoma cell lines Part (II):

IC₅₀ % (µg/ml) of newly synthesized compounds on human liver carcinoma cell line (HEPG2), human breast cancer cell line

(MCF-7) (Table 2 & Fig.3).

Comp. No.	Inhibition concentration (50%) (IC ₅₀) µg/ml	
	HEPG-II	MCF-7
1	33.6	120.09
2	63.6	103.22
3	8.24	60.34
4	12.81	8.51
5	35.1	5.68
6	57.9	95.02
7	3.8	68.7
8	20.2	21.5
9	7.6	6.9
10	10.3	125.5
11	140.98	32
12	45.3	87.2
13	66.9	21.7
14	23.3	34.2
15	74.6	42.5
16	49.7	11.2




Fig. 3. Antiproliferative activity of the compounds against human carcinoma cell lines (HEPG2), (MCF-7).

On the other hand, all compounds showed moderate to good antifungal activity towards (*Candida albicans* and *Aspergillus flavin*) except compounds (2,7,10,14,16) which showed no antifungal activity compared to positive control (Amphotericin B).

From Table 2, the results showed that compounds (7,9,2,10,3) were the most active recording IC₅₀% values in the order (3.8, 7.6, 8.24, 10.3, 12.81) µg/ml against HEPG-II cell line. On the other hand, the compounds (5,9,3,16) showed to be the most active recording IC₅₀% values in the order (5.68, 6.9, 8.51, 11.2) µg/ml against MCF-7 cell line.

References

- Zygmunt Kazimireczu, Jacqueline A. Upcroft, Peterupcroft, Agata Gorska, Bohdan Starosciak and Agnieszka Laudy, Synthesis, antiprotozoal and antibacterial activity of nitro- andhalogeno-substituted benzimidazole derivatives) *Acta Biochimica Polonica*, **49**, No.1 ,185-195 (2002)
- Ashish Kumar Tewari & Anil Mishra, Synthesis and antiviral activities of N-Substituted-2-substituted-benzimidazole derivatives), *Indian Journal of Chemistry*, **Vol 54B**, pp. 489-493 (2006)
- Avinash Patil, Swastica Gangulgy and Sanjay Surana,(A Systematic review of Benzimidazole Derivatives as an Antiulcer Agent). *RJC Rasayan J. Chem*, Vol.1 No.3,447-460. 2008
- Michele Tonelli , Matteo Simone , Bruno Tasso, Federica Novelli,Vito Boido, Fabio Sparatore, Giueppepalietti,Sabrinaprcl, Gabriele Giliberti, Sylvain Blois, Cristina (Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives,El SEVIER, 2937-2953. , (2010),
- Vishvanath D. Patil, GoleMeha, Mhartre Shramesha, JaiswalAarti,(A mild and efficient synthesis of Benzimidazole by using lead peroxide under solvent free condition) peagia Research Library, (2010) , 125-129.
- SahooBiswa Mohan, Behera T.P. ,Ravi Kumar B.V.V.,Microwave Irradiation Versus Conventional Method: Synthesis of Benzimidazolyl Chalcone Derivatives), *Chem. Tech* (sep 2010),**Vol 2** , No.3, pp.1634-1637.
- Hanan M. Refaat, (Synthesis and Anticancer Activity of Some Novel 2-Substituted Benzimidazole Derivatives). *El SEVIER*, (2010), 45, 2949-2956
- DAVOOD AZARIFAR,MOJAN PIRHAYATI, BEHROOZ MALEK, MEHRANGIZ SANGINABADI and RAZIEH NEJAT YAMI, (Acetic acid-promoted condensation of o-phenylenediamine with aldehydes into 2-aryl-1-(arylmethyl)-1H-benzimidazoles under microwave irradiation), *Journal of the Serbian chemical society* (2010),75 (9), 1181-1189.
- Rondla Rohini, Kanneshnker, P. Muralidhar Reddy and Vadde Ravinder ,(Synthesis and Antimicrobial of a Activities New Class of 6-Arylbenzimidazo [1,2-c] quinazolines),*J. Braz. Chem. Soc.* (2010), Vol.21, N0.1,49-57.
- Ramanpreet Walia , Ms. Hedaitullah , Syeda Farha Naaz , Khalid Iqbal and HS. Lamba., (BENZIMIDAZOLE DERIVATIVES – AN OVERVIEW) *IJRPC* (2011) .1 (3).
- Parmendersingh Rathee , Ritu Dhakar, Sunny Bhardawaj, Monika Gupta and Rakesh Kumar, (Synthesis and Antimicrobial studies of novel Benzimidazole derivatives). *Journal of Applied Pharmaceutical Science* , 2011 , 01 (04) ,127-130.
- Janardansingh Yadav and Y.K. Srivasta (Microwave assisted rapid and efficient synthesis, characterization and pharmacological evaluation of some novel benzimidazole assembled 1,5-benzodizepine and 1,5-benzothiazepine derivatives), *Scholars Research Library* , 2011, 3(2),284-291.
- Ingle, R.G. and Magar, D.D. , (Heterocyclic Chemistry of Benzimidazoles and Potential Activities of Derivatives) *Jadoun Science*, 2011,**Vol.1**,(1),26-32.
- Fawzia Zakaria El- Aablack, (Synthesis of Some New Benzimidazole Derivatives of Pharmaceutical Interest). *E-J.Chem.* **8** (2), 748-752.(2011)
- Ramesh Dhani, Gopnath Chakka, M.V. Saicharon Teja, P. Mastaniah, Avinash, P. Raja Rathnam, Saleha Naginas, K.V. Chadanasilpa, Dhana Lakshmik, (Synthesis and characterization of 2-mercaptobenzimidazole), *I JAPAN*, 1(3), 111-113 (2011)

16. P. Csontos, S., N. Pan deya, Ashishk. Pathak, (Benzimidazole : A Versatile Chemical Entity) *IJAPAN* (2011), 2 (6) 1726-1737.
17. Sami Sajjadifar, Seyed Ahmed Mirshokraie, Nematollah Javahereshan, Omid Louie (SBSA as a New and Efficient Catalyst for the One-Pot Green Synthesis of Benzimidazole Derivatives at Room Temperature), *American Journal of Organic Chemistry*, 2012, 212 : 1-6.
18. Namratesingh, Annamaliapandurangan, Kavita Rana, preeti Anand, Arshad Ahmed, Amit Kumar Tiwari, (Benzimidazole: A short review of their antimicrobial activities), *International Current Pharmaceutical Journal*, 1(5), 119-127 (2012)
19. Amanpreet S. Kohli, S.R. Wakode, (Synthesis of Some Benzimidazole Derivatives and Evaluation of their Antimicrobial Activity), *International of pharmaceutical Frontiers Research*, 2 (2), 56-67 (2012)
20. VAIDEHI, B.N.B. and GNANADEEPIKA, K. (Synthesis and Biological Evaluation of 2-Substituted Benzimidazoles), *International Journal of Pharma and Bio Science*, 3 (3), p. 26-31. (2012)
21. Chunxia Chen, Chen Chen, Binili, Jingwei Tao and Jinsongpeng, (Aqueous Synthesis of 1-H-2-Substituted Benzimidazoles via Transition-Metal-Free Intramolecular Amination of Aryl Iodides) *Molecules*, 17, 12506-12520 (2012)
22. Uday Kalidhar, Rajinder Kumar, Aman Deep Kaur, (Synthesis, Spectral Studies and Biological Evaluation of Some Benzimidazole Derivatives containing Sulfonamide), *Research Journal of Pharmaceutical Science*, Vol (3) issue 2 Page No.1072.2012,
23. Nassir N. Al- Mohamed, Yatimah Alias, Zanariah Abdullah, Raied M. Shair, Ekhlass M. Taha and Aidil Abdul Hamid, (Synthesis and Antibacterial Evaluation of Some Novel Imidazole and Benzimidazole Sulfonamides), *Molecules*, 18, 11978-1995 (2013)
24. Singh Gurvinder, Kaur Maninderjit, Chander Mohan, (Benzimidazoles: The Latest Information on Biological Activities), *International Research Journal of Pharmacy*, 4 (1) (2013)
25. Hany J. Al-Najjar, Assem Barakat, Abdullah M. Al-Magid, Yahia N. Mabkhot, Manuel Weber, Hazem A. Ghabbour and Hoong-Kun Fun (A Greener, Efficient Approach to Michael Addition of Barbituric acid to Nitroalkene in aqueous Diethylamine Medium), *Molecules*, 19, 1150-1162. (2014)
26. Marzoug S. Al-Thebeiti, Raz (Synthesis of some new thiazolo[3,3-a]pyridines and related heterocyclic systems), *ELSEVIER*, 55, 109-118 (2000).
27. Mazaaher Kidwai, Ruby Thakur, and Richa Mohan, (Ecofriendly Synthesis of Novel Antifungal (Thio) Barbituric Acid Derivatives), *Acta Chim*, 52, 88-92 (2005)
28. Ghodsi Mohammadi Ziarani, Sakineh Farmazi, Shima Asadi, Alireza Badii, Roya Bazland Massoud Amalou, (Three-component synthesis of pyrano[2,3-d]-pyrimidine dione derivatives facilitated by sulfonic acid nanoporous silica (SBA-Pr-SO₃H) and their docking and urease inhibitory activity), *DARU Journal Pharmaceutical Science*, 1-13. (2013)
29. Gayathri Banda, S.M.H. Hipparagi, Ramjith, U.S, Cyril Mathews Jacob, (Microwave Assisted Synthesis of Fluoro, Chloro 2-Substituted Benzimidazole Thiazine Derivatives for Antibacterial and Analgesic.
30. Anshulchawla, Ramandeepkaur and Anju Goyal, (Importance of Microwave Reactions in the Synthesis of Novel Benzimidazole Derivatives) *Journal of Chemical and Pharmaceutical Research*, 925-944 (2011)
31. A.W. Bauer, W.W.M. Kirby, J.C. Sherris and M. Turck, (Antibiotic susceptibility testing by a standardized single disc method), 36 (3), 493-496. (1966)
32. T. Mosmann, (Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, *J. Imm.* 56, 55-63. (1983)

(Received: 24/11/2015;

accepted : 15/5/2016)

تحضير بعض المركبات الحلقية الغير المتجانسة عديدة الأنوية من 1-باي فينيل-4-يل-(-1-ميثيل-بنزيميدازول-2-يل)-بيوت-2-اين-1-أون مع توقع النشاط البيولوجي لهذه المركبات

نعيمة محمود ، إيناس عز الدين إسلام و إيناس حسن

كلية العلوم - جامعة الأزهر - مدينة نصر والهيئة المصرية للمصل واللقاح - القاهرة - مصر

الإضافة النيوكليوفيلية لحمض الباربيتوريك ، حمض الثيوجليكوليك مع المالنونيتريل وايضا-3 أمينو-5-بيرازولينون مع-1 باي فينيل-4-يل-(-1-ميثيل- بنزيميدازول-2-يل)- بيوت-2-اين-1-أون (1) ليعطوا مشتقات اليريميدين، الثيازول والبيرازولينون (2-4) على التوالي. ويتفاعل المركب (4) مع الأريليدين-مالونيتريل في الميثانول يعطى مشتق البيريدين (5). ويتكاتف الشالكون (1) مع ثيويوريا في ايثانوليك هيدروكسيد الصوديوم مكونا مشتق الثيازين (6) التي عولجت بخليط من (البرومين وحمض الخليك) مكونا مركب (7). وايضا، بحلقة شالكون (1) مع اورثوفينيلين داى امين في حمض الخليك الثلجى مكونا مشتق الديازيبين (8) . ايضا تفاعل شالكون (1) مع-3 أمينو-5-بيرازولينون في الكحول الإيثيلي مكونا مشتق البيرازولينون (9) . (مخطط 1). ويتكاتف مركب (1) مع-2-سبانو اسيتو هيدرازيد في وجود حامض مكونا قاعدة شيف (10). التي بالتسخين في حمض الخليك (96%) تكون مشتق البيرازولينون (11) والتي بتفاعلها مع كلوريد اكسيد الفوسفور مكونا مشتق الكلوروبيرازول (12) الذى تفاعل مع الأمينات الثانوية وأعطى مشتقات البيرازول ذات المستبدلات الأمينية (13 أ-ج) على التوالي. من جهة اخرى ، تكونت قاعدة شيف (14) من تكاتف المركب (1) مع-2 أمينو-2-(-هيدروكسى ميثيل) بروبان 1،3- - دايول في الكحول الإيثيلي والذي تم تفاعله مع كلوريد اكسيد الفوسفور ليعطى مشتق البروبانول (15). وأخيرا، تم حلقة المركب (1) مع-2 أمينو فينول و-2 أمينو ثيازول في البنزين الجاف ليعطى المركبات (16 ، 17) على التوالي (مخطط 2).